A clinical trial has started in Perth, Australia, evaluating a lightweight, gel-free, waterproof wearable ECG patch designed for continuous cardiac monitoring for up to 14 days. Developed from RMIT University work and advanced by startup Lubdub, the device is being worn by patients who otherwise would receive Holter monitoring at Midlands Medical Specialists. The company cites earlier volunteer testing showing cleaner signal quality than standard Holter devices, which could reduce clinician time spent filtering noise and improve diagnostic throughput. The trial’s outcome—whether the patch can generate medical-grade rhythm data in real-world conditions—will shape adoption prospects for extended ambulatory monitoring aimed at catching cardiovascular events earlier.
Get the Daily Brief